Valion Bio Inc. Common Stock (VBIO)
Stock · NASDAQ · Health Care
$1.15as of 10/16/2026
Price chart
Active signals
VBIO Signal Track Record
How signals performed across all stocks →What VBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 22 | -17.4% | 23% | September 24, 2026 |
| Bollinger Band Breakdown | 20 | -16.6% | 30% | August 18, 2026 |
| Bollinger Band Breakout | 21 | -26.5% | 5% | August 31, 2026 |
| Any 20-session window (baseline) | -14.8% | 25% |
Computed by MarketWall from daily closing prices since August 29, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VBIO
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 52
- Website
- tivichealth.com
Fundamentals
- 1-day range
- $1.13$1.24
- Market cap
- $1.14M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-8.23
- Dividend yield
- —
- Beta
- 3.82
- Avg. volume
- 1.71M
How Valion Bio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 21, 2025 · via SEC EDGAR / Finnhub
Valion Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VBIOValion Bio Inc. Common Stock$1.17▼ 4.88%Market cap $1.14MP/E —$1.11$32.5
- ITOCiTonic Holdings Ltd Class A Ordinary Shares$3.84▼ 4.24%Market cap $4.94MP/E —$3.51$18.4
- NUWENuwellis Inc. Common Stock$0.55▲ 0.00%Market cap $5.26MP/E 0.03$0.4444$172.9
- NDRAENDRA Life Sciences Inc. Common Stock$4.74▼ 7.06%Market cap $5.68MP/E —$2.96$8
- NXLNexalin Technology Inc. Common Stock$2.35▼ 4.08%Market cap $7.45MP/E —$2.38$50.7
- IRIXIRIDEX Corporation Common Stock$0.81▼ 1.22%Market cap $14.61MP/E —$0.607$1.65
- QTIQT Imaging Holdings Inc. Common Stock$2.4▲ 0.84%Market cap $37.38MP/E —$2.38$19.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VBIO Valion Bio Inc. Common Stock | $1.14M | — | $1.17 | ▼ 4.88% | $1.11$32.5 |
| ITOC iTonic Holdings Ltd Class A Ordinary Shares | $4.94M | — | $3.84 | ▼ 4.24% | $3.51$18.4 |
| NUWE Nuwellis Inc. Common Stock | $5.26M | 0.03 | $0.55 | ▲ 0.00% | $0.4444$172.9 |
| NDRA ENDRA Life Sciences Inc. Common Stock | $5.68M | — | $4.74 | ▼ 7.06% | $2.96$8 |
| NXL Nexalin Technology Inc. Common Stock | $7.45M | — | $2.35 | ▼ 4.08% | $2.38$50.7 |
| IRIX IRIDEX Corporation Common Stock | $14.61M | — | $0.81 | ▼ 1.22% | $0.607$1.65 |
| QTI QT Imaging Holdings Inc. Common Stock | $37.38M | — | $2.4 | ▲ 0.84% | $2.38$19.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Valion Bio's Velocity Biowork Subsidiary Completes Initial Feasibility Evaluation Of LarmorBio's BioScan-NMR Platformbenzinga · 10/15/2026
- Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data CentersYahoo · 10/9/2026
- New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of EntolimodYahoo · 10/5/2026
- Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development PathwayYahoo · 9/30/2026
- Wednesday's pre-market session: top gainers and losersChartMill · 9/30/2026
- Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term OpportunityYahoo · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 9/30/2026
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 9/24/2026
- Wondering what's happening in today's pre-market session?ChartMill · 9/24/2026
Insider Activity
Insider Actions →- Zikria Dean · September 22, 2026 · Grant50.0K
- Lisa G. Wolf · September 18, 2026 · Option Exercise4
- Lisa G. Wolf · September 18, 2026 · Tax Withholding2 @ $2.12
- Michael K. Handley · May 18, 2026 · Option Exercise2.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 264.2K
- Total value held
- $196.5K
- Institutional holders
- 9
- Unknown87.8K
- Unknown61.2K
- Unknown59.3K
- Unknown42.4K
- Unknown10.5K
- Unknown2.4K
- Unknown584
- Unknown16
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Valion Bio Completes Oral Mucosal Entolimod Formulation
Valion Bio has successfully formulated an oral mucosal version of entolimod in partnership with Shear Kershman Laboratories. The company states this development could open a needle-free pathway and significantly expand its long-term opportunity. This news contributed to the stock appearing in pre-market movers, though the shares remain well below their 52-week high of $32.50.
Valion Bio Completes Oral Mucosal Entolimod Formulation. Valion Bio has successfully formulated an oral mucosal version of entolimod in partnership with Shear Kershman Laboratories. The company states this development could open a needle-free pathway and significantly expand its long-term opportunity. This news contributed to the stock appearing in pre-market movers, though the shares remain well below their 52-week high of $32.50.